CD9-HM396-100μg / 询价
CD9-HM396-500μg / 询价
CD9-HM396-500μgx2 / 询价
Human CD96/TACTILE Protein
Recombinant Human CD96/TACTILE Protein is expressed from HEK293 with mFc (IgG1) tag at the C-Terminus.It contains Val22-Met503 [Accession | P40200-2].
The protein has a predicted MW of 79.8 kDa. Due to glycosylation, the protein migrates to 120-160 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CD96 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human CD96, mFc Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Human CD155, hFc Tag with the EC50 of 0.19μg/ml determined by ELISA (QC Test).
Immobilized Human CD96, mFc Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-CD96 Antibody, hFc Tag with the EC50 of 31.8ng/ml determined by ELISA.
The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
CD96 molecule; CD96; DKFZp667E2122; TACTILE
(1) Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clin Cancer Res. 2016 Nov 1;22(21):5183-5188. doi: 10.1158/1078-0432.CCR-16-0933. Epub 2016 Sep 12. PMID: 27620276.
